限制谱成像与非侵入性生物标志物预测主动监测前列腺穿刺升级的前瞻性比较
研究前瞻性纳入2016年1月至2019年6月接受重复穿刺的前列腺癌主动监测患者,比较限制谱成像(RSI-MRI)信号图与30种生物标志物预测穿刺升级或再分类的能力。RSI-MRI的AUC最高(0.84;95%CI:0.71-0.96),非影像生物标志物中前列腺体积校正的前列腺健康指数密度(PHI)AUC为0.68(95%CI:0.53-0.82)。RSI-MRI、PIRADS和PHI可提高检测主动监测穿刺升级的预测能力。
要点
- RSI-MRI信号图预测主动监测穿刺升级的AUC为0.84(95%CI:0.71-0.96)。
- 非影像生物标志物中前列腺体积校正的PHI密度AUC为0.68(95%CI:0.53-0.82)。
- 非影像生物标志物对下次穿刺升级预测作用可忽略,但改善总体进展时间的预测。
核心结论
- RSI-MRI、PIRADS和PHI可提高检测主动监测穿刺升级的预测能力,其中RSI-MRI信号输出是主动监测穿刺检出临床显著前列腺癌的最强预测因子。
研究设计与样本
- 前瞻性纳入2016年1月至2019年6月接受重复穿刺的前列腺癌主动监测患者,获取MRI和生物标志物以预测升级。
- 受试者接受前列腺多参数MRI和短时程弥散加权增强MRI(RSI)生成限制信号图,并评估30种生物标志物(14种临床流行病学特征、9种分子生物标志物和7种影像相关特征)。
- 主要结局为后续主动监测前列腺穿刺升级或再分类,统计分析包括AUROC和AUPRC的操作特征改善。
主要发现
- 个体生物标志物中受试者操作特征曲线下面积(AUC)最高者为RSI-MRI(AUC=0.84;95%CI:0.71-0.96)。
- 最佳非影像生物标志物为前列腺体积校正的前列腺健康指数密度(PHI,AUC=0.68;95%CI:0.53-0.82)。
- 非影像生物标志物对下次穿刺升级的预测作用可忽略,但确实改善主动监测中总体进展时间的预测。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Protocol-based active surveillance (AS) biopsies have led to poor compliance. To move to risk-based protocols, more accurate imaging biomarkers are needed to predict upgrading on AS prostate biopsy. We compared restriction spectrum imaging (RSI-MRI) generated signal maps as a biomarker to other available non-invasive biomarkers to predict upgrading or reclassification on an AS biopsy. METHODS: We prospectively enrolled men on prostate cancer AS undergoing repeat biopsy from January 2016 to June 2019 to obtain an MRI and biomarkers to predict upgrading. Subjects underwent a prostate multiparametric MRI and a short duration, diffusion-weighted enhanced MRI called RSI to generate a restricted signal map along with evaluation of 30 biomarkers (14 clinico-epidemiologic features, 9 molecular biomarkers, and 7 radiologic-associated features). Our primary outcome was upgrading or reclassification on subsequent AS prostate biopsy. Statistical analysis included operating characteristic improvement using AUROC and AUPRC. RESULTS: The individual biomarker with the highest area under the receiver operator characteristic curve (AUC) was RSI-MRI (AUC = 0.84; 95% CI: 0.71-0.96). The best non-imaging biomarker was prostate volume-corrected Prostate Health Index density (PHI, AUC = 0.68; 95% CI: 0.53-0.82). Non-imaging biomarkers had a negligible effect on predicting upgrading at the next biopsy but did improve predictions of overall time to progression in AS. CONCLUSIONS: RSI-MRI, PIRADS, and PHI could improve the predictive ability to detect upgrading in AS. The strongest predictor of clinically significant prostate cancer on AS biopsy was RSI-MRI signal output.
引用
- Eng SE, Basasie B, Lam A, et al. Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy. Prostate Cancer Prostatic Dis. 2022. PMID: 36097168. doi:10.1038/s41391-022-00591-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。